Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. (OTCQB: ADMT) is regularly featured in company news as a technology-based developer and manufacturer of proprietary electronic medical devices, contract engineering and manufacturing services, and eco-friendly water-based formulations. Its releases provide updates on financial performance, research and development activity, and progress on key medical and veterinary technologies.
Recent ADMT news has focused on quarterly and annual financial results, where the company discusses revenues, gross profit, operating expenses, and income or loss from operations across segments such as electronics, engineering services, and chemical-related activities. These reports often highlight trends in revenue growth or declines, the impact of inflation and component supply on margins, and the effect of R&D priorities on segment performance.
A central theme in ADMT’s news coverage is the development and commercialization of its Sonotron® technology. The company reports ongoing R&D on a human medical version of Sonotron, a non-invasive therapeutic device intended for musculoskeletal pain conditions, and its intention to pursue a 510(k) submission to the FDA once development is complete. ADMT also issues updates on Vet-Sonotron®, the veterinary version of this technology, including completion of R&D, commencement of production, initial commercialization, pre-orders, distributor relationships, and presentations at industry webinars and shareholder video calls.
Investors and observers following ADMT news can expect coverage of earnings releases, segment performance, R&D milestones for Sonotron and Vet-Sonotron, commentary on operating conditions, and information about the company’s contract medical device engineering and manufacturing services. This news page aggregates such announcements to help readers track ADMT’s disclosed developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ADM Tronics Unlimited, Inc. (OTCQB: ADMT) reported its third fiscal quarter results for FY 2023, highlighting a net income of $155,148 for the nine months ended December 31, 2022, a turnaround from a net loss of $140,221 a year prior. Revenues surged over 31% to $3,044,838 compared to $2,322,871 for the same period in 2021. The Electronics segment alone saw a revenue increase of over 73%. For the latest quarter, ADMT also posted a net income of $93,771, contrasting a net loss of $72,393 for the same quarter last year. The company attributes its revenue growth to all three operational segments: Electronics, Engineering, and Chemical.
ADM Tronics Unlimited (OTCQB: ADMT) reported a 27% increase in revenues for Q1 FY2023, totaling $921,408 compared to $721,358 in the prior year. Despite facing challenges from supply chain issues and increased raw material costs, the company maintained a 42% gross profit margin. R&D expenses decreased by 23%, reflecting the nearing completion of the Vet-Sonotron technology development. Loss from operations also improved, decreasing by 20% to $34,625. ADMT anticipates continued revenue growth.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) announced fiscal results for the year ending March 31, 2022, showing revenues of $3.21 million, a 4% increase from the prior year. Gross profit rose to $1.25 million, approximately 39% of revenues. Operating expenses increased to $2.38 million, leading to a net loss of $1.38 million. The company remains focused on the commercialization of its Vet-Sonotron technology despite ongoing supply chain issues. Positive future growth opportunities are anticipated from both Vet-Sonotron and the upcoming Sonotron Mark 2.
FAQ
What is the current stock price of Adm Tronics (ADMT)?
What is the market cap of Adm Tronics (ADMT)?
